GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
35.06
+0.25 (+0.72%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close34.81
Open35.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range34.97 - 35.22
52 Week Range34.72 - 44.54
Volume4,224,506
Avg. Volume4,543,958
Market Cap82.825B
Beta0.90
PE Ratio (TTM)33.97
EPS (TTM)1.03
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.01 (5.75%)
Ex-Dividend Date2017-11-09
1y Target Est43.67
Trade prices are not sourced from all markets
  • Business Wire32 minutes ago

    GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application with the US Food and Drug Administration for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease .

  • MarketWatch15 hours ago

    ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. ...

  • Barrons.com16 hours ago

    Gilead: The Leader of the Pack…or Just Another Follower?

    Shares of Gilead Sciences (GILD) are higher on Wednesday morning, and RBC Capital Markets' Brian Abrahams thinks they'll keep rising.  Abrahams and his team reiterated and Outperform rating and $96 price target on Gilead today, a day after the Food and Drug Administration updated labels for competitor GlaxoSmithKline's (GSK)/ViiV dolutegravir-based HIV treatments to include risk of liver toxicity, even in patients without risk factors, and now recommends monitoring. While that may be unfortunate for patients, it's good news for Gilead, Abrahams writes, given that it makes its products look more competitive. More detail from the note: We see this new AE warning and monitoring requirement for ViiV as a potential long-term advantage to help GILD maintain its HIV leadership.

  • J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
    Zacks17 hours ago

    J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

    J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

  • Novartis (NVS) Receives EC Nod for Tasigna Label Expansion
    Zacks18 hours ago

    Novartis (NVS) Receives EC Nod for Tasigna Label Expansion

    Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

  • Market Realist19 hours ago

    A Look into the Performance of Merck’s Vaccine Portfolio in 3Q17

    In 3Q17, Merck’s (MRK) Gardasil and Gardasil 9 generated revenue of $675 million, which reflected a ~22% fall YoY (year-over-year) and ~44% growth QoQ (quarter-over-quarter). Lower sales in the US market…...

  • Reuters23 hours ago

    U.S. FDA approves first two-drug HIV regimen in win for GSK

    The green light is a boost for GlaxoSmithKline (GSK.L), whose Chief Executive Emma Walmsley counts the medicine among three products that are "critical" to help fill a revenue gap left by falling sales of the ageing lung drug Advair. The other two are a three-in-one inhaler for chronic lung disease and a shingles vaccine, which were approved in September and October. The new HIV treatment, called Juluca, is a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, and is available to patients who have been on a stable regimen for at least six months.

  • Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
    PR Newswireyesterday

    Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

    LONDON , Nov. 21, 2017 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that ...

  • Reutersyesterday

    U.S. FDA approves first two-drug HIV regimen from GSK

    The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines. The treatment, called Juluca, is a fixed-dose tablet that combines two previously approved drugs, dolutegravir and rilpivirine, and is available to patients who have been on a stable regimen for at least six months. Juluca belongs to GlaxoSmithKline Plc's majority-owned ViiV Healthcare, in which Pfizer Inc and Shionogi also have small stakes.

  • Is GlaxoSmithKline plc (LSE:GSK) Undervalued?
    Simply Wall St.3 days ago

    Is GlaxoSmithKline plc (LSE:GSK) Undervalued?

    Let’s talk about the popular GlaxoSmithKline plc (LSE:GSK). The company’s shares saw significant share price volatility over the past couple of months on the LSE, rising to the highs ofRead More...

  • ACCESSWIRE3 days ago

    Corporate News Blog - GlaxoSmithKline and Innoviva’s Trelegy Ellipta Gets Marketing Authorization for the Treatment of COPD in Europe

    LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK ) ("GSK"), following ...

  • Theravance Shares Rise on Approval of Glaxo's COPD Therapy
    Zacks5 days ago

    Theravance Shares Rise on Approval of Glaxo's COPD Therapy

    Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

  • Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
    Zacks5 days ago

    Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

    Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

  • Market Realist7 days ago

    AstraZeneca’s Valuation after 3Q17 Earnings

    In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

  • Reuters7 days ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's (GSK.L) new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S). The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.

  • Reuters7 days ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis. The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.

  • Business Wire7 days ago

    Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

  • The Wall Street Journal7 days ago

    [$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases

    The Crown Prince of Abu Dhabi launched a fund with the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis, which leads to a condition known as elephantiasis.

  • Benzinga8 days ago

    VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO

    VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...

  • AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
    Zacks8 days ago

    AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

    AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

  • Market Realist8 days ago

    Behind Novartis’s Respiratory Drug Performance in 3Q17

    In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.

  • 9 More Companies Whose Dividend Is in Danger
    InvestorPlace8 days ago

    9 More Companies Whose Dividend Is in Danger

    All things considered, it can’t be terribly surprising General Electric Company (NYSE:GE) opted to reduce its dividend. The relatively new CEO John Flannery flat-out told shareholders he was mulling the possibility back in October! In no certain order, here’s a closer look at ten more dividend stocks that could soon see a dividend cut of their own.

  • Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
    Zacks9 days ago

    Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

    GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.

  • Top LSE Dividend Picks For The Day
    Simply Wall St.9 days ago

    Top LSE Dividend Picks For The Day

    A great investment for income investors with a long time horizon is in dividend-paying companies like British American Tobacco. Dividend stocks are a safe bet to increase your portfolio valueRead More...

  • VBI: Multiple Platforms Yield a Portfolio of Vaccines
    Zacks Small Cap Research10 days ago

    VBI: Multiple Platforms Yield a Portfolio of Vaccines

    NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...